Andrea Pfeifer
Known title: Chief Executive OfficerCIK: 0001697107
Andrea Pfeifer's purchase track record
Andrea Pfeifer has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/15/2026 | ACIU | $31K | -24.8% | -23.6% | +9.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ACIU | ▼ Sell | Open Market | 10,000 | $28K | 5/15/2026 | View on chart |
| ACIU | ▲ Buy | Open Market | 10,000 | $31K | 4/15/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
AC Immune Parkinson’s Vaccine Study Meets Safety and Immunogenicity Goals
AC Immune’s Parkinson’s vaccine study reached its safety and immunogenicity targets, a key milestone for the company’s pipeline. The company also reported ongoing progress in its ACI-7104 program and other pipeline expansions. This development comes as the stock trades near its 52‑week low, with a support level at $2.76.
AC Immune Parkinson’s Vaccine Study Meets Safety and Immunogenicity Goals. AC Immune’s Parkinson’s vaccine study reached its safety and immunogenicity targets, a key milestone for the company’s pipeline. The company also reported ongoing progress in its ACI-7104 program and other pipeline expansions. This development comes as the stock trades near its 52‑week low, with a support level at $2.76.